Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with <i>BRAF</i> or <i>KRAS</i> Mutations.

Yao, Yung-Mae M; Donoho, Gregory P; Iversen, Philip W; Zhang, Youyan; Van Horn, Robert D; Forest, Amelie; Novosiadly, Ruslan D; Webster, Yue Wang; Ebert, Philip; Bray, Steven; Ting, Jason C; Aggarwal, Amit; Henry, James R; Tiu, Ramon V; Plowman, Gregory D; Peng, Sheng-Bin

Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.

Yao, Yung-Mae M; Donoho, Gregory P; Iversen, Philip W; Zhang, Youyan; Van Horn, Robert D; Forest, Amelie; Novosiadly, Ruslan D; Webster, Yue Wang; Ebert, Philip; Bray, Steven; Ting, Jason C; Aggarwal, Amit; Henry, James R; Tiu, Ramon V; Plowman, Gregory D; Peng, Sheng-Bin.

Afiliação

Yao YM; Oncology Discovery Research, Eli Lilly and Company, New York, New York.
Donoho GP; Oncology Discovery Research, Oncology Business Unit, Eli Lilly and Company, Indianapolis, Indiana.
Iversen PW; Statistics, Oncology Business Unit, Eli Lilly and Company, Indianapolis, Indiana.
Zhang Y; Oncology Discovery Research, Oncology Business Unit, Eli Lilly and Company, Indianapolis, Indiana.
Van Horn RD; Oncology Discovery Research, Oncology Business Unit, Eli Lilly and Company, Indianapolis, Indiana.
Forest A; Oncology Discovery Research, Eli Lilly and Company, New York, New York.
Novosiadly RD; Oncology Discovery Research, Eli Lilly and Company, New York, New York.
Webster YW; IT Bioinformatics, Oncology Business Unit, Eli Lilly and Company, Indianapolis, Indiana.
Ebert P; Oncology Discovery Research, Oncology Business Unit, Eli Lilly and Company, Indianapolis, Indiana.
Bray S; Oncology Discovery Research, Oncology Business Unit, Eli Lilly and Company, Indianapolis, Indiana.
Ting JC; Oncology Discovery Research, Oncology Business Unit, Eli Lilly and Company, Indianapolis, Indiana.
Aggarwal A; Oncology Discovery Research, Oncology Business Unit, Eli Lilly and Company, Indianapolis, Indiana.
Henry JR; Discovery Chemistry, Oncology Business Unit, Eli Lilly and Company, Indianapolis, Indiana.
Tiu RV; EarlyPhase Oncology, Oncology Business Unit, Eli Lilly and Company, Indianapolis, Indiana.
Plowman GD; Oncology Discovery Research, Eli Lilly and Company, New York, New York.
Peng SB; Oncology Discovery Research, Oncology Business Unit, Eli Lilly and Company, Indianapolis, Indiana.

Clin Cancer Res ; 23(18): 5547-5560, 2017 Sep 15.

Article em En | MEDLINE | ID: mdl-28611205

Assuntos

Antineoplásicos/farmacologia; Neoplasias Colorretais/genética; Receptores ErbB/antagonistas & inibidores; Receptores ErbB/genética; Mutação; Inibidores de Proteínas Quinases/farmacologia; Proteínas Proto-Oncogênicas B-raf/antagonistas & inibidores; Proteínas Proto-Oncogênicas B-raf/genética; Animais; Biomarcadores Tumorais; Linhagem Celular Tumoral; Cetuximab/farmacologia; Neoplasias Colorretais/tratamento farmacológico; Neoplasias Colorretais/mortalidade; Neoplasias Colorretais/patologia; Modelos Animais de Doenças; Quimioterapia Combinada; Receptores ErbB/metabolismo; Humanos; Ligantes; Camundongos; Compostos de Fenilureia/farmacologia; Polimorfismo de Nucleotídeo Único; Proteínas Proto-Oncogênicas B-raf/metabolismo; Pirimidinas/farmacologia; Taxa de Sobrevida; Resultado do Tratamento; Ensaios Antitumorais Modelo de Xenoenxerto

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Proteínas Proto-Oncogênicas B-raf / Inibidores de Proteínas Quinases / Receptores ErbB / Mutação / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google